Context: Fetuses exposed to an obese intrauterine environment are more likely to be born large-forgestational age (LGA) and are at increased risk of obesity in childhood and cardiovascular disease and/or type 2 diabetes mellitus as adults, but which factors that influence the intrauterine environment is less clear.
T he intrauterine environment is an important determinant of birth size, body composition, and subsequent metabolic development. Thus, fetuses exposed to an obese intrauterine environment are more likely to be born large-for-gestational age (LGA) and are at increased risk of obesity in childhood (1) and cardiovascular disease and/or type 2 diabetes mellitus (T2DM) as adults (2, 3) . In addition to body mass index (BMI), maternal factors known to impact birth weight are age, parity, and various mechanisms limiting nutrient supply to the fetus like placental size, whereas a smaller proportion is linked to genetic factors (2, 4) .
Pregnancy induces a number of metabolic changes to ensure a continuous nutrient supply to the fetus. These metabolic changes include a decrease in insulin sensitivity, and increase and redistribution of maternal adipose tissue, among others. The adipose tissue is an active endocrine organ and secretes the adipokines adiponectin and leptin. Adiponectin decreases from mid pregnancy, whereas leptin increases throughout pregnancy (5) (6) (7) . Secretion of leptin is positively associated with percentage body fat and represents a satiety signal to regulate energy balance (8) . Excessive production of leptin is a consequence of resistance to its effect on target organs (9) , and increased levels are associated with high BMI and insulin resistance in T2DM (10) . Leptin is known to be produced within the intrauterine environment (11) and correlates with a number of fetal growth estimates (12) . In contrast to leptin, adiponectin has antidiabetic properties and correlates inversely with body weight and fat mass (13) . In experimental models, genetic knockdown of adiponectin increased fetal growth (14) and adiponectin supplementation restored maternal insulin sensitivity, normalized placental function, and reduced excessive fetal growth in mice (15) . However, clinical data on the association between adiponectin and birth weight are scarcer (16, 17) .
The aim of this study was to investigate the association between maternal leptin and adiponectin, measured multiple times during pregnancy in a prospective cohort of 300 women, and birth weight and prevalence of LGA or small-for-gestational age (SGA). In addition, we investigated the association between birth weight and messenger RNA (mRNA) expression of adiponectin receptors and genes involved in nutrient transport in the placenta of 30 women.
Methods
The STORK study (STORe barn og Komplikasjoner, translated as Large Babies and Complications) was a prospective cohort study with a longitudinal design in which 1031 low-risk women of Scandinavian heritage were followed throughout their pregnancy and gave birth at Oslo University Hospital Rikshospitalet between 2002 and 2008 (4). Briefly, each pregnant woman had four antenatal visits at weeks 14 to 16, 22 to 24, 30 to 32, and 36 to 38. A 75-g oral glucose tolerance test (OGTT) was performed on all women at 14 to 16 and 30 to 32 weeks of gestation. The follow-up study was performed 5 years after the index pregnancy (18) . Exclusion criteria included pregnancy at the time of invitation and delivery within the past year. Three hundred women agreed to participate. Subjects included in this study are participants included in the follow-up study using samples from pregnancy [i.e., a substudy of the STORK study (STORe barn og Komplikasjoner, translated as Large Babies and Complications)]. Written informed consent was obtained from all participants in the study. All clinical investigations were conducted according to the principles in the Declaration of Helsinki. The study was approved by the Regional Committee for Medical Research Ethics of Southern Norway in Oslo, Norway.
Appropriate-for-gestational age, LGA, and SGA Infants were divided according to birth weight: appropriatefor-gestational age (AGA), between 10th and 90th percentile;
LGA, .90th percentile; and SGA, ,10th percentile, adjusted for gestational age and fetal sex, according to Norwegian reference curves (19) .
Intrauterine measurements of fetal growth
Ultrasound measurement was performed and head circumference (HC), femur length (FL), and abdominal circumference (AC) at 22 to 24, 30 to 32, and 36 to 38 weeks was recorded.
Measurements of glycemic and adipokine parameters
All 75-g OGTTs were performed in the morning after an overnight fast and glucose measured as previously reported (18) . Total adiponectin and leptin were measured in duplicate using commercially available reagents by enzyme-immunoassay (EIA; R & D Systems, Minneapolis, MN) in a 384-format using the combination of a SELMA (Jena, Germany) pipetting robot and a BioTek dispenser/washer (EL406) and plate reader (Synergy H1 Hybrid, BioTek, Winooski, VT), as previously published (7).
Diagnosis of gestational diabetes mellitus and preeclampsia
Gestational diabetes mellitus (GDM) was diagnosed on a 75-g OGTT using the World Health Organization criteria from 1999: 2-hour plasma glucose $7.8 mmol/L (20) and the International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria; fasting plasma glucose 5.1 to 6.9 mmol/L, 1-hour plasma glucose $10.0 mmol/L or 2-hour plasma glucose 8.5 to 11.0 mmol/L. Insulin sensitivity, homeostatic model assessment of insulin resistance (HOMA-IR), and insulin resistance were calculated as previously reported (18) . Preeclampsia was diagnosed by new-onset blood pressure $140/90 mm Hg and significant proteinuria (urinary total protein-to-creatinine ratio .30 or +1 on urine dipstick). All cases were diagnosed after 34 weeks' gestation (late-onset preeclampsia).
Collection, storage, and RNA extraction of placental biopsies
Blocks of 2 to 4 cm were taken from the placental parenchyma, briefly washed in phosphate buffer saline, and snap frozen in liquid nitrogen. Half of the biopsy was homogenized in TRIzol reagent (Invitrogen, Life Technologies, Carlsbad, CA) on ice with a tissue grinder (Sigma Aldrich, St. Louis, MO).
Total RNA was extracted using TRIzol reagent (Invitrogen, Life Technologies) and purified with RNeasy microkit columns (Qiagen, Hilden, Germany) as previously published (21) .
RNA sequencing
Sequencing libraries were prepared from 500 ng of total RNA using the TruSeq RNA sample preparation reagents (Illumina, San Diego, CA) according to the manufacturer's instructions, with fragmentation for 4 minutes at 94°C. The libraries were sequenced using 125 bp paired-end sequencing on an Illumina HiSEquation 2000. We recorded an average 22.3 million (range, 20.2-24.6 million) paired reads per sample. Fastq files were generated using bcl2fastq (v1.8.4). Sequence reads were mapped to the reference genome (hg19/GRCh38) using TopHat2 (v2.0.13) and Bowtie2 (v.2.2.3.0). Library sizes and standard deviations for input into TopHat were calculated empirically by aligning 1,000,000 reads to an index built from human cDNA sequence. Sequence alignment was guided using only previously annotated gene models downloaded from Ensembl (Homo_sapiens.GRCh38.79.gtf). On average, there was 73.6% concordant read pair mapping (range 69.6-76.6), with a mean unique mapping of 94.1%. Raw expression counts were calculated per gene using featureCounts and the same gtf file that was used for the read alignment. Differential expressed genes in RNA sequencing (RNAseq) data were tested using DESeq2 (22) package for R dividing the samples between LGA and AGA groups. Outlier detection (Cook distance cutoff) and filtering out low expressed genes were performed using the default method in DESeq2, as previously published (21) .
Statistical analysis
Statistical analyses were conducted using SPSS for Windows, version 21.0 (Chicago, IL). In general, data are expressed as mean 6 standard deviation when normally distributed and median (25th, 75th percentile) when skewed. Differences in the temporal course of leptin and adiponectin during pregnancy between birth weight groups were evaluated with repeated measures ANOVA a priori, with or without gestational age, fetal sex, birth weight, parity, and BMI as covariates. Bonferroni adjusted t tests between different groups were performed a posteriori. Data from this analysis are expressed as geometric means and 95% confidence intervals. The birth weight groups (SGA, LGA, and AGA) and birth weight were adjusted for gestational age and fetal sex. The association between change in adiponectin from the first to last visit in pregnancy and birth weight was assessed with linear regression adjusting for other predictors. Associations between mRNA transcripts and birth weight were evaluated by Spearman correlation. Two-tailed P values , 0.05 were considered significant, except for interactions analysis where P , 0.01 was considered significant. The RNAseq results were not adjusted according to Benjamini and Hochberg and unadjusted P values are presented. Table 1 shows the characteristics of the study population.
Results
Adiponectin decreases most during pregnancy in mothers giving birth to LGA infants
As shown in Fig. 1(a) , plasma adiponectin decreased from 14 to 16 weeks to 36 to 38 weeks for all participants, but most in the group of mothers with the LGA infants. We found an interaction (P = 0.007) between the temporal course of adiponectin during pregnancy and birth weight categories (AGA, LGA, and SGA). Post hoc analysis revealed differences in adiponectin levels between AGA and LGA at 22 to 24 (P = 0.016) and 36 to 38 weeks (P = 0.004). In contrast, an increase from 14 to 16 weeks to 30 to 32 weeks was observed for leptin during pregnancy [ Fig. 1(b) ]. An interaction between leptin during pregnancy and birth weight categories was observed (P , 0.001) and post hoc analysis showed differences in leptin levels at weeks 14 to 16 between AGA and LGA (P = 0.047). No significant differences were found between the group of AGA and SGA, and we therefore excluded SGA from further analysis.
As shown in Fig. 1I , when adjusting for known factors influencing birth weight, parity, BMI at weeks 14 to 16, and change in HOMA-IR from 14 to 16 weeks to 36 to 38 weeks, we still observed an interaction between adiponectin during pregnancy and birth weight categories (AGA vs LGA; P = 0.002) and difference in adiponectin levels at 22 to 24 (P = 0.033) and 36 to 38 weeks (P = 0.010). After adjusting for the same factors, leptin levels were not significant between AGA and LGA groups during pregnancy, and no interaction [P = 0.108; Fig.  1(d) ] was observed. On this notion, we decided to focus on adiponectin in further analyses. Importantly, the association between adiponectin and birth weight categories was not affected by the addition of gestational weight gain to the model shown previously (interaction value P = 0.003).
Change of adiponectin during pregnancy is associated with birth weight A larger decline in adiponectin from 14 to 16 weeks to 36 to 38 weeks was observed in mothers who gave birth to LGA infants [22056 (23807, 2554)] vs AGA infants [2886 (23031, 677), P = 0.01], and this effect was present also after adjustment for baseline adiponectin, BMI, and change in HOMA-IR from 14 to 16 weeks to 36 to 38 weeks (P = 0.001). The decline in adiponectin in women who gave birth to LGA infants was most prominent early in pregnancy (weeks 14-16 to [22] [23] [24] and further analysis revealed a larger decline (P = 0.012) in LGA (21220 [23497, 68]) vs AGA mothers (2495 [22119, 2672]) also after adjustment (P = 0.011). We next investigated the association between change in adiponectin and birth weight in a regression model adjusted for parity, gestational weight gain, glucose at weeks 14 to 16 and change in HOMA-IR (Table 2) . We found that the adiponectin change was associated with birth weight in the multivariable regression analysis together with previous known factors as parity, BMI, and gestational weight gain. Replacing the change in HOMA-IR with change in glucose during pregnancy did not impact the result.
Increased intrauterine AC at 36 to 38 weeks is associated with low adiponectin levels throughout pregnancy
To further investigate how the intrauterine fetal growth was associated with maternal adiponectin levels during pregnancy, we included data on AC, HC, and FL at weeks 36 to 38 in tertiles. The rational was to test whether use of other fetal growth indicators than birth weight also were related to maternal adiponectin levels. We found an interaction between the temporal course of adiponectin during pregnancy and AC tertiles (P = 0.098). Post hoc analysis revealed lower adiponectin levels in women with a higher fetal AC (i.e., tertile 3) Figure 1 . Circulating levels of (a) adiponectin and (b) leptin during pregnancy in mothers who gave birth to AGA, LGA, and SGA infants. Adjusted (gestational age, fetal sex, birth weight, parity, BMI weeks 14-16, change in HOMA-IR weeks 14-16 to 36-38) circulating levels of (c) adiponectin and (d) leptin during pregnancy in mothers who gave birth to AGA and LGA infants. Data are given as geometric mean and 95% confidence interval. The P values represent the interaction between the groups (birth weight) and time. *P , 0.05; **P , 0.001. doi: 10.1210/jc.2017-00289 https://academic.oup.com/jcemcompared with low fetal AC (i.e., tertile 1) at weeks 22 to 24 (P = 0.001), 30 to 32 (P = 0.011), and 36 to 38 [P = 0.003; Fig. 2(a) ]. In addition, adiponectin levels were lower in women with mid tertile AC compared with tertile 1 at 22 to 24 (P = 0.046) and 36 to 38 (P = 0.026).
After adjusted for gestational age, sex, parity, BMI at weeks 14 to 16, and change in HOMA-IR from 14 to 16 weeks to 36 to 38 weeks, we still found an interaction between the temporal course of maternal adiponectin levels and AC (P = 0.084) with lower adiponectin levels at weeks 22 to 24 (P = 0.032) and 36 to 38 (P = 0.023) in women with high, compared with women with low fetal size AC at 36 to 38 weeks [ Fig. 2(b) ]. For HC and FL, we found no significant interactions or differences between the groups in unadjusted or adjusted analysis (data not shown).
Decreased levels of adiponectin receptor 2 and system A amino acid transporter expression in term placentas from LGA infants To further examine the relationship between adiponectin and birth weight, we next analyzed the expression of the adiponectin receptors and nutrients transporters that could be influenced by adiponectin in placenta tissue from a previously published RNAseq analysis data set (21) . We found a negative correlation in the whole material (n = 30) between ADIPOR2 and birth weight (r = 20.56, P = 0.001) and intrauterine AC at visit 4 [r = 20.40, P = 0.036; Fig. 3(a) ], but no association was found when investigating ADIPOR1 (birth weight r = 0.13, P = 0.484; intrauterine AC r = 0.04, P = 0.831). Similarly, dividing the samples into LGA vs AGA placentas (n = 8 vs 22), a decreased level of ADIPOR2 mRNA [ Fig. 3(b) ], but not ADIPOR1 (P = 0.64), was observed in the LGA placentas. Investigating genes from the main nutrient transport systems and focusing on the 20 highest expressed (involved in mTOR, IGF1 system, transport of glucose, amino acid, fatty acid, lipoprotein) (23) [Fig. 3(c) ], we found that most of these (70%) were associated with ADIPOR1 mRNA expression. An extended list is presented in the Supplemental Data. Only system A amino acid transporter (SNAT2) was negatively correlated with birth weight, and positively with ADI-POR2 [ Fig. 3(d) ]. Accordingly, SNAT2 expression was lower in LGA placentas (P = 0.01). There was no significant difference between the placenta biopsy groups of LGA and AGA in fetal sex, anesthesia use, cesarean section, or number of women with GDM or preeclampsia.
Discussion
The current study investigated the association between leptin and adiponectin during pregnancy and birth weight in a prospective cohort of 300 women. There are some previous data on an association between low adiponectin levels and birth weight (16, 17) as also seen in the current study. However, our findings herein clearly extend these previous findings in several ways. (1) Adiponectin decreased most from early to late pregnancy in mothers who gave birth to LGA offspring, and this decrease was an independent predictor of birth weight. (2) Circulating adiponectin levels were lower in mothers where the offspring had highest AC late in pregnancy. (3) The decrease in systemic adiponectin levels in mothers who gave birth to LGA offspring accompanied a placental decrease in mRNA levels of the adiponectin receptor ADIPOR2. Our findings suggest that maternal adiponectin may be an important predictor of fetal growth and birth weight, independent of BMI, gestational weight gain, and insulin resistance.
Previous studies have shown that conditions where insulin resistance occurs, including obesity, T2DM, and GDM, the subjects have low adiponectin levels (7, 24) . Also during a normal pregnancy, in the absence of obesity, adiponectin decreases (5, 25) , as demonstrated in the current study. Redistribution of adipose tissue (25) and insulin resistance (26) are closely associated with adiponectin during pregnancy, but it is unclear whether impaired insulin action is the cause or consequence of adiponectinaemia (25) . We found that adiponectin was lower, and decreased more in mothers who gave birth to LGA infants. Importantly, this finding was also present after adjusting for known factors influencing birth weight, i.e., index BMI, gestational weight gain, and insulin resistance. In contrast, there was no difference in leptin levels following adjustment, suggesting that leptin levels mainly reflect increased fat content during pregnancy. Our data suggest that adiponectin may have independent effects on birth weight, other than reflecting fat content and insulin resistance, and that low levels may contribute to the development of LGA infants.
Sonographic measurement of fetal AC can be used as a proxy for the development of in utero fetal growth (27) . A review of randomized controlled trials (27) that used AC $75th percentile adjusted for gestational age in second and third trimester to identify fetuses at high risk for being born LGA and to stratify medical therapy found evidence that the ultrasound-based strategy resulted in better pregnancy outcomes, with lower prevalence of LGA and macrosomia. Furthermore, although LGA infants of diabetic mothers had an accelerated rate of fetal AC growth in the early third trimester, normal rates of HC and FL growth were observed (28) , indicating that AC may be a more reliable indicator of fetal metabolic state. Our study shows that maternal adiponectin levels are lowest when the fetus has the highest AC measurements at weeks 36 to 38. No differences in HC and FL were observed, suggesting that maternal adiponectin levels could reflect metabolic differences in the fetuses.
Adiponectin that may influence placental function mainly originates from maternal adipose tissue because maternal adiponectin does not cross the placenta or is produced/expressed in the placenta (29) . Adiponectin effects are mediated through two specific receptors, ADIPOR1 and ADIPOR2, which have divergent roles in mediating metabolic functions (30) . Our study shows a decreased mRNA expression of ADIPOR2 in placentas from LGA infants and negative correlation with birth weight. A decreased expression of adiponectin receptors has been found in the skeletal muscle of patients with T2DM (31) and ob/ob mice (32) . Reduced plasma adiponectin and reduced adiponectin receptor expression may contribute to a "vicious cycle" with reduced adiponectin sensitivity and may lead to insulin resistance (33) . Fetal growth is directly related to maternal nutrient availability and the placentas ability to transport these nutrients to the fetus (34) . In adiponectin deficient mice, adiponectin suppressed fetal growth by increasing IGFBP-1 in trophoblasts in the placenta, thereby reducing IGF-1 bioavailability to the fetus (14) . In addition, adiponectin supplementation in pregnant obese dams prevented fetal overgrowth by normalizing insulin and mTOR signaling and nutrient transport in the placenta (15) . Our finding that adiponectin signaling may influence fetal growth is supported by our finding that mRNA expression of ADIPOR1 in placental tissue was strongly correlated with multiple genes involved in nutrient transport including mTOR activation, glucose transport (INSR1, GLUT1, multiple IGFBPs), and amino acid transport. Thus, decreased adiponectin levels could potentially affect fetal growth through ADIPOR1. However, only SNAT2 was negatively correlated with birth weight and not correlated with ADIPOR1 but with ADIPOR2. SNAT2 is part of system A transport system and facilitates the transport of both nonessential and essential amino acids (35) . The placenta may function as a nutrient sensor and restrict growth when nutrients are limited and accelerate growth when nutrients are in excess (36) . An alternate hypothesis suggests that the placenta may respond in a compensatory manner in response to low and high substrate levels, in an effort to maintain normal fetal growth (37) . Contrary to our study, primary human trophoblast incubated with adiponectin inhibited system A activity and SNAT2 expression (38) . However, studies in placenta tissues have shown that system A activity is increased in microvillous plasma membrane from placenta isolated from large infants of obese women (35) , unaffected in lean nondiabetic women giving birth to LGA fetuses (39) , and reduced in diabetic pregnancies associated with fetal macrosomia (40), supporting both nutrient sensing and compensatory mechanisms. Taken together, our finding that SNAT2 correlated with ADI-POR2 and birth weight may suggest that adiponectin could influence fetal growth and propensity to be born LGA through mechanisms involved in system A transport. However, caution is needed when interpreting these data due to their descriptive nature. Further limitations to our study are the lack of protein data and regulation of signaling, and we can therefore not include any mechanistic explanation of our results.
The question why the adiponectin levels decrease extensively during pregnancy in some women independent of BMI and insulin resistance remains to be answered. One interesting area is the interaction between high-density lipoprotein cholesterol (HDL-C) and adiponectin. Adiponectin is strongly associated with HDL-C, independent of adiposity and insulin sensitivity (41), and Goldberg et al. (42) found a correlation between change in adiponectin and change in HDL-C. Adiponectin is known to shift the distribution of HDL from smaller to larger particles leading to increased HDL-C levels. It is also possible that causality is reversed and a decrease in HDL-C may lead to decrease in adiponectin levels (43) . ApoA-I gene transfer in mice caused an increase in plasma concentrations of adiponectin, and HDL-C treatment of cultured adipocytes promoted adiponectin expression (44) . Thus, because HDL-C levels decrease in pregnancy, largely independent of lifestyle factors and demographics (45) , it is tempting to speculate that interactions between adiponectin and HDL-C could partly explain the low levels of adiponectin in certain women independent of glucose metabolism and body mass.
Our data demonstrate lower adiponectin levels during pregnancy in women with fetuses with high intrauterine AC and in women giving birth to LGA infants. Change in the level of adiponectin was an important predictor of birth weight, independent of BMI and insulin resistance. A decreased expression of ADIPOR2 and SNAT2 were found in placentas from LGA infants, and future mechanistic studies are needed to evaluate the interaction between ADIPOR2, SNAT2 signaling, and birth weight.
